?

Curriculum Vitae

?

NAME: Hongbing Mei

?

POSITION TITLE: Professor

?

EDUCATION/TRAINING

?

A. Personal statement

Hongbing Mei is currently Chief Physician and the Director of the Urology Department of Shenzhen Second People's Hospital (the First Affiliated Hospital of Shenzhen University). Dr. Mei is also the Deputy Director of the Institute of Urology at Shenzhen University, and serves as a Master’s supervisor at Guangzhou Medical University, Shenzhen University Health Science Center, Anhui Medical University and Shantou University. In addition, he serves as an adjunct professor of Surgery at Southern Medical University, Shenzhen University

and Anhui Medical University.

Dr. Mei obtained his doctorate from Tongji Medical College of HUST(Huazhong University of Science and Technology) in July 2004, and was a visiting scholar at Duke University Medical Center in the United States in 2017. Dr. Mei’s primary research interests are the diagnosis and treatment of urinary tumors, and he is particularly skilled at using intracavitary, minimally intrusive technology for the surgical diagnosis and treatment of urinary system tumors, unitary calculus, benign prostatic hyperplasia and adrenal diseases.

He has given several keynote speeches on prostate cancer and bladder cancer at conferences at home and

abroad, and has hosted and participated in a wealth of scientific research projects, including a subproject of the National High-tech R&D Program (863 Program), a national key research and development program, and three projects funded by the National Natural Science Foundation. He has published more than 50 articles in the Journal of Experimental & Clinical Cancer Research, Experimental Cell Research, Biomed Research International, Cancer Biomarker, OncoTargets, Therapy, and other international academic journals; with 14 of these articles being indexed by SCI. He also edits journals such as Urinary Calculus and Modern Bladder Oncology, and attended the 32^nd training class of Chinese Urology “Talent Project” in May 2018.

?

B. Positions and honors

Positions

2018-present: Department Director, Urological Surgery Department of Shenzhen Second People’s Hospital (First Affiliated Hospital of Shenzhen University), Shenzhen, China

2012-2018: Vice Director, Urological Surgery Department of Shenzhen Second People’s Hospital (First Affiliated Hospital of Shenzhen University), Shenzhen, China

2010-2012: Chief Physician, Urological Surgery Department of Shenzhen Second People’s Hospital (First Affiliated Hospital of Shenzhen University), Shenzhen, China

2006-2010: Associate Chief Physician, Urological Surgery Department of Shenzhen Second People’s Hospital (First Affiliated Hospital of Shenzhen University), Shenzhen, China

2004-2006: Attending Physician, Urological Surgery Department of Shenzhen Second People’s Hospital (First Affiliated Hospital of Shenzhen University), Shenzhen, China

1992-1999: Attending Physician; Surgeon, Jingzhou Third People’s Hospital, Jingzhou, China

?

Honors

(1) Member of the International Alliance of Urolithiasis

(2) Member of CUA Infection and Inflammation Group

(3) Member of the Urology Branch of the Guangdong Medical Association

(4) Standing Committee Member of the Urology Specialty Committee of the Guangdong Association of Integrative Traditional and Western Medicine

(5) Vice Chairman of the Prostate Disease Branch of the Guangdong Urological and Reproductive Association

(6) Vice Chairman of the Kidney Surgery Society of the Guangdong Urological and Reproductive Association

(7) Standing Committee Member of the Urology and Oncology Branch of the Guangdong Urological and Reproductive Association

(8) Vice Chairman of the Urology Branch of the Shenzhen Medical Association

(9) Vice President of the Urology Branch of the Shenzhen Medical Doctor Association

(10) Team leader of the Oncology Group of the Urology Branch of the Shenzhen Medical Association

(11) Recipient of the “2017 Hurun·PingAn Good Doctors of China”?award

(12) Recipient of the “2018 Excellent Master Supervisor of Shenzhen University” award

?

C. Representative publications (selected publications in recent five years)

(1) Hongbing Mei#，Yuhan Liu#, Qun Zhou#, Kun Hu# and Yuchen Liu (2019) Long noncoding RNA MALAT1 acts as a potential biomarker in cancer diagnosis and detection: a meta-analysis.?Biomarkers in medicine, 13(1): 45-54.

(2) Yuhan Liu#, Mengting Ding#, Xinhui Liao#, Qunjun Gao#, Anbang He, Baoer Liu, Kun Hu, Haibiao Xie, Qun Zhou, Hengji Zhan, Yuchen Liu*, Weiren Huang* and Hongbing Mei*?(2018) High expression of enhancer RNA MARC1 or its activation by DHT is associated with the malignant behavior in bladder cancer. Experimental Cell Research,?370(2): 303-311.

(3) Yuhan Liu#, Mengting Ding#, Qunjun Gao#, Anbang He, Yuchen Liu* and Hongbing Mei*?(2018) Current Advances on the Important Roles of Enhancer RNAs in Gene Regulation and Cancer. Biomed Research International, 2018:2405351.

(4) Yuhan Liu#,?Anbang He#,?Baoer Liu,?Yucheng Zhong,?Xinhui Liao,?Jiangeng Yang,?Jieqing Chen,?Jianting Wu and Hongbing Mei* (2018)?rs11614913 polymorphism in miRNA-196a2 and cancer risk: an updated meta-analysis. Oncotagerts and Therapy,?11: 1121-1139.

(5) Xinhui Liao#, Jieqing Chen#, Yuchen Liu, Anbang He, Jianting Wu, Jianli?Cheng, Xintao Zhang, Zhaojie Lv, Feng Wang and Hongbing Mei*?(2018) Knockdown of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibition, apoptosis and motility reduction in bladder cancer. Cancer Biomarkers,?21(2): 277-285.

(6) Anbang He#, Rong Hu#, Zhicong Chen#, Xinhui Liao#, Jianfa Li, Dailian Wang, Zhaojie Lv, Yuchen Liu, Feng Wang and Hongbing Mei*. (2017) Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a meta-analysis. Oncotarget, 8(1):1937-1943.

(7) Jiangeng Yang#, Yuchen Liu, Anbang He, Yuhan Liu, Jianting Wu, Xinhui Liao, Zhaojie Lv, Feng Wang and?Hongbing Mei?*?(2017) Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget,?8(40):68721-68729.

(8) Anbang He#, Song Feng, Zhicong Chen, Yuhan Liu and Hongbing Mei*?(2017) Long non-coding RNA BRAF activated non-coding RNA as a potential novel molecular biomarker for metastasis and prognosis in various cancers. Minerva Medica,?108(3):293-298.

(9) Anbang He#, Yuchen Liu#, Zhicong Chen#, Jianfa Li, Mingwei Chen, Li Liu, Xinhui Liao, Zhaojie Lv, Yonghao Zhan, Chengle Zhuang, Junhao Lin, Weiren Huang* and Hongbing Mei*?(2016) Over-expression of long noncoding RNA BANCR inhibits malignant phenotypes of?human bladder cancer. Journal of Experimental & Clinical Cancer Research, 35(1):125.

(10) Anbang He#, Zhicong Chen#, Hongbing Mei* and Yuchen Liu*?(2016) Decreased expression of LncRNA MIR31HG in human bladder cancer. Cancer Biomarkers, 17(2):231-6.

?

D. Research support

Ongoing projects (RMB￥200000)

1.?Natural Science Foundation of Shenzhen Science and Technology innovation Committee (Study on the mechanism of VGLL4 regulating the growth of bladder cancer cells) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?2020 to 2022

PI: Hongbing Mei ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ￥100000

?

2.?Clinical Research Project Fund of Shenzhen Second People's Hospital (To evaluate the prognosis of novel endogenous therapy or chemotherapy by detecting the expression level of ar-v7 gene in peripheral blood exosomes of patients with metastatic castration-resistant prostate cancer (mCRPC) by qPCR; grant no. 20193357027)

2019 to 2022

PI: Hongbing Mei ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ￥100000

?

?

?

?